Novartis enhances data access

Share this article:

Novartis announced Wednesday that it upped its transparency initiative and that researchers will now be able to tap into patient-level data for drugs approved in the US and EU. The company also announced Wednesday that it was enhancing its Clinical Study Report summaries so the findings will be available in what the company described in a statement as “easy to understand consumer language” by the end of 2014.

Novartis said these summaries will also include “additional interpretation of data.”

The drugmaker is one of several companies that have touted their efforts to make data more accessible. Others include GlaxoSmithKline and J&J subsidiary Janssen.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.